Jul 8 |
GRI Bio regains compliance with Nasdaq
|
Jul 8 |
GRI Bio Regains Compliance with Nasdaq
|
Jul 2 |
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
|
Jul 1 |
GRI Bio to Present at the 8th Annual IPF Summit
|
Jun 28 |
GRI Bio Announces Closing of $4.0 Million Public Offering
|
Jun 27 |
GRI Bio announces pricing of $4 million public offering
|
Jun 27 |
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
|
Jun 27 |
GRI Bio Announces Pricing of $4 Million Public Offering
|
Jun 20 |
GRI Bio files to offer shares of common stock
|
Jun 14 |
GRI Bio announces 1-for-13 reverse stock split
|